相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
Tiantian Ma et al.
ANNALS OF HEMATOLOGY (2019)
Anti-BCMA antibodies in the future management of multiple myeloma
Maria Gavriatopoulou et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models
Zoe Shancer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Suzanne Trudel et al.
BLOOD CANCER JOURNAL (2019)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.
Lu Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma
Cesar Sommer et al.
MOLECULAR THERAPY (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Frans V. Suurs et al.
PHARMACOLOGY & THERAPEUTICS (2019)
leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Jie Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells
Haiming Chen et al.
LEUKEMIA RESEARCH (2019)
Serum BCMA Levels Predict Outcomes for Patients with MGUS and Smoldering Multiple Myeloma (SMM)
Angela Dispenzieri et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Cell-based immunotherapy approaches for multiple myeloma
Katharina Kriegsmann et al.
BRITISH JOURNAL OF CANCER (2019)
Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells
Krista Kinneer et al.
LEUKEMIA (2019)
A compound chimeric antigen receptor strategy for targeting multiple myeloma
K. H. Chen et al.
LEUKEMIA (2018)
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
C. S. Chim et al.
LEUKEMIA (2018)
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Arnab Ghosh et al.
LEUKEMIA & LYMPHOMA (2018)
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma
Eric Sanchez et al.
TARGETED ONCOLOGY (2018)
CARs and other T cell therapies for MM: The clinical experience
Sophia Danhof et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker
Eric Sanchez et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2018)
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
Kevin M. Friedman et al.
HUMAN GENE THERAPY (2018)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma
Dalia A. Salem et al.
LEUKEMIA RESEARCH (2018)
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
Eric L. Smith et al.
MOLECULAR THERAPY (2018)
CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment
Clare Y. Slaney et al.
CANCER DISCOVERY (2018)
Cynomolgus monkey plasma cell gene signature to quantify the in vivoactivity of a half-life extended anti-BCMA BiTE® for the treatment of multiple myeloma
Ana Goyos et al.
CANCER RESEARCH (2018)
HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma
Andreas Pahl et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.
Yarong Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.
Noopur S. Raje et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma.
Ben Buelow et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Shih-Feng Cho et al.
FRONTIERS IN IMMUNOLOGY (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
Suzanne Trudel et al.
LANCET ONCOLOGY (2018)
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
Sophie Viaud et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Allogeneic CAR-T Cells: More than Ease of Access?
Charlotte Graham et al.
CELLS (2018)
Engineering an Optimized Trimeric APRIL-Based CAR to Broaden Targetability of Multiple Myeloma
Andrea Schmidts et al.
BLOOD (2018)
Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy
Nina Shah et al.
BLOOD (2018)
Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study
Xiaolan Shi et al.
BLOOD (2018)
HDP101, a Novel B-Cell Maturation Antigen (BCMA)-Targeted Antibody Conjugated to α-Amanitin, Is Active Against Myeloma with Preferential Efficacy Against Pre-Clinical Models of Deletion 17p
Ram Kumar Singh et al.
BLOOD (2018)
Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study
Max S. Topp et al.
BLOOD (2018)
Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma
Damian J. Green et al.
BLOOD (2018)
Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Tara Gregory et al.
BLOOD (2018)
Low Dose of Human scFv-Derived BCMA-Targeted CAR-T Cells Achieved Fast Response and High Complete Remission in Patients with Relapsed/Refractory Multiple Myeloma
Songfu Jiang et al.
BLOOD (2018)
T Cells Expressing Anti B-Cell Maturation Antigen Chimeric Antigen Receptors for Plasma Cell Malignancies
Chunrui Li et al.
BLOOD (2018)
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial
Sham Mailankody et al.
BLOOD (2018)
A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
Don M. Benson et al.
BLOOD (2018)
Baseline and Early Changes in Serum B-Cell Maturation Antigen Levels Predict Progression Free Survival and Response Status for Multiple Myeloma Patients in a Phase 1 Trial Evaluating Ruxolitinib, Lenalidomide and Methylprednisolone
Sean Bujarski et al.
BLOOD (2018)
REGN5458, a Bispecific BCMAxCD3 T Cell Engaging Antibody, Demonstrates Robust In Vitro and In Vivo Anti-Tumor Efficacy in Multiple Myeloma Models, Comparable to That of BCMA CAR T Cells
David J. Dilillo et al.
BLOOD (2018)
A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma
Alexander M. Lesokhin et al.
BLOOD (2018)
Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8+ cytotoxic T Lymphocytes Against Multiple Myeloma
Jooeun Bae et al.
BLOOD (2018)
An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
Lydia Lee et al.
BLOOD (2018)
Redirecting T cells to hematological malignancies with bispecific antibodies
Mireya Paulina Velasquez et al.
BLOOD (2018)
Chimeric Antigen Receptor-T Cell Therapy Practical Considerations for Implementation in Europe
Jochen Buechner et al.
HEMASPHERE (2018)
SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads
Krista Kinneer et al.
CLINICAL CANCER RESEARCH (2018)
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Michael Ghermezi et al.
HAEMATOLOGICA (2017)
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Michael Ghermezi et al.
HAEMATOLOGICA (2017)
Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement
Elisabeth Schuh et al.
JOURNAL OF IMMUNOLOGY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Novel Immunotherapies for Multiple Myeloma
Mattia D'Agostino et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Global Manufacturing of CAR T Cell Therapy
Bruce L. Levine et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis
Nikhil C. Munshi et al.
JAMA ONCOLOGY (2017)
Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing
Sandra L. Ross et al.
PLOS ONE (2017)
Chimeric antigen receptor T-cell therapies for multiple myeloma
Lekha Mikkilineni et al.
BLOOD (2017)
Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts
Jessica Hartmann et al.
EMBO MOLECULAR MEDICINE (2017)
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger et al.
CANCER CELL (2017)
Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies
Kevin A. Hay et al.
DRUGS (2017)
Changes in Serum B-Cell Maturation Antigen Levels Are a Rapid and Reliable Indicator of Treatment Efficacy for Patients with Multiple Myeloma
Kyle Udd et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States
Luciano J. Costa et al.
BLOOD ADVANCES (2017)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
Yu-Tzu Tai et al.
BLOOD (2016)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
Lydia Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma
Eric Sanchez et al.
CLINICAL CANCER RESEARCH (2016)
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
Marcela V. Maus et al.
CLINICAL CANCER RESEARCH (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Multiple Myeloma: Diagnosis and Treatment
S. Vincent Rajkumar et al.
MAYO CLINIC PROCEEDINGS (2016)
Current Trends of Renal Impairment in Multiple Myeloma
Punit Yadav et al.
KIDNEY DISEASES (2016)
New Insights into the Mechanism of Action (MoA) of First-in-Class IgG-Based Bcma T-Cell Bispecific Antibody (TCB) for the Treatment of Multiple Myeloma (MM)
Laura Moreno et al.
BLOOD (2016)
First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation
Adam D. Cohen et al.
BLOOD (2016)
New criteria for response assessment: role of minimal residual disease in multiple myeloma
Bruno Paiva et al.
BLOOD (2015)
Multiplex Genome-Edited T-cell Manufacturing Platform for Off-the-Shelf Adoptive T-cell Immunotherapies
Laurent Poirot et al.
CANCER RESEARCH (2015)
γ-secretase directly sheds the survival receptor BCMA from plasma cells
Sarah A. Laurent et al.
NATURE COMMUNICATIONS (2015)
Bispecific T-cell engagers for cancer immunotherapy
Amelia M. Huehls et al.
IMMUNOLOGY AND CELL BIOLOGY (2015)
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2014)
Curing myeloma at last: defining criteria and providing the evidence
Bart Barlogie et al.
BLOOD (2014)
Robust isolation of malignant plasma cells in multiple myeloma
Ildiko Frigyesi et al.
BLOOD (2014)
Zoom Zoom: Racing CARs for Multiple Myeloma
Marcela V. Maus et al.
CLINICAL CANCER RESEARCH (2013)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
Production of stable bispecific IgG1 by controlled Fab-arm exchange Scalability from bench to large-scale manufacturing by application of standard approaches
Michael J. Gramer et al.
MABS (2013)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
IMWG consensus on maintenance therapy in multiple myeloma
Heinz Ludwig et al.
BLOOD (2012)
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease
Robert C. Rickert et al.
IMMUNOLOGICAL REVIEWS (2011)
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
AJ Novak et al.
BLOOD (2004)
BCMA is essential for the survival of long-lived bone marrow plasma cells
BP O'Connor et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses
SL Xu et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth
P Rennert et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
